{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:50:48Z","timestamp":1776408648587,"version":"3.51.2"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Japan Science and Technology Agency Moonshot R&D Program","award":["JPMJMS2022-4"],"award-info":[{"award-number":["JPMJMS2022-4"]}]},{"name":"Japan Society for the Promotion of Science (JSPS) KAKENHI","award":["JP21H05051"],"award-info":[{"award-number":["JP21H05051"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24ck0106794h0002"],"award-info":[{"award-number":["JP24ck0106794h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06939-9","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T01:26:59Z","timestamp":1773192419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clonal analysis of a case with fluid overload-associated large B-cell lymphoma evolving from primary large B-cell lymphoma of the central nervous system"],"prefix":"10.1007","volume":"105","author":[{"given":"Yuta","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko Miyagi","family":"Maeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Hosoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Narita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"7","key":"6939_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, Bhagat G, Borges AM, Boyer D, Calaminici M, Chadburn A, Chan JKC, Cheuk W, Chng W-J, Choi JK, Chuang S-S, Coupland SE, Czader M, Dave SS, de Jong D, Du M-Q, Elenitoba-Johnson KS, Ferry J, Geyer J, Gratzinger D, Guitart J, Gujral S, Harris M, Harrison CJ, Hartmann S, Hochhaus A, Jansen PM, Karube K, Kempf W, Khoury J, Kimura H, Klapper W, Kovach AE, Kumar S, Lazar AJ, Lazzi S, Leoncini L, Leung N, Leventaki V, Li X-Q, Lim MS, Liu W-P, Louissaint A, Marcogliese A, Medeiros LJ, Michal M, Miranda RN, Mitteldorf C, Montes-Moreno S, Morice W, Nardi V, Naresh KN, Natkunam Y, Ng S-B, Oschlies I, Ott G, Parrens M, Pulitzer M, Rajkumar SV, Rawstron AC, Rech K, Rosenwald A, Said J, Sarkozy C, Sayed S, Saygin C, Schuh A, Sewell W, Siebert R, Sohani AR, Tooze R, Traverse-Glehen A, Vega F, Vergier B, Wechalekar AD, Wood B, Xerri L, Xiao W (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"issue":"18","key":"6939_CR2","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1182\/bloodadvances.2020002293","volume":"4","author":"D Kaji","year":"2020","unstructured":"Kaji D, Ota Y, Sato Y, Nagafuji K, Ueda Y, Okamoto M, Terasaki Y, Tsuyama N, Matsue K, Kinoshita T, Yamamoto G, Taniguchi S, Chiba S, Ohshima K, Izutsu K (2020) Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis. Blood Adv 4(18):4442\u20134450. https:\/\/doi.org\/10.1182\/bloodadvances.2020002293","journal-title":"Blood Adv"},{"issue":"8","key":"6939_CR3","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1111\/cas.15427","volume":"113","author":"S Fukuhara","year":"2022","unstructured":"Fukuhara S, Oshikawa-Kumade Y, Kogure Y, Shingaki S, Kariyazono H, Kikukawa Y, Koya J, Saito Y, Tabata M, Yoshifuji K, Mizuno K, Miyagi-Maeshima A, Matsushita H, Sugiyama M, Ogawa C, Inamoto Y, Fukuda T, Sugano M, Yamauchi N, Minami Y, Hirata M, Yoshida T, Kohno T, Kohsaka S, Mano H, Shiraishi Y, Ogawa S, Izutsu K, Kataoka K (2022) Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. Cancer Sci 113(8):2763\u20132777. https:\/\/doi.org\/10.1111\/cas.15427","journal-title":"Cancer Sci"},{"issue":"2","key":"6939_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11060-006-9165-6","volume":"80","author":"K Jahnke","year":"2006","unstructured":"Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, Korfel A (2006) Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol 80(2):159\u2013165. https:\/\/doi.org\/10.1007\/s11060-006-9165-6","journal-title":"J Neurooncol"},{"issue":"2","key":"6939_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11060-020-03446-3","volume":"147","author":"MP Patel","year":"2020","unstructured":"Patel MP, Kirkpatrick JP, Johnson MO, Healy P, Herndon JE, Lipp ES, Miller ES, Desjardins A, Randazzo D, Friedman HS, Ashley DM, Peters KB (2020) Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. J Neurooncol 147(2):477\u2013483. https:\/\/doi.org\/10.1007\/s11060-020-03446-3","journal-title":"J Neurooncol"},{"issue":"7","key":"6939_CR6","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/s41375-022-01582-5","volume":"36","author":"AJM Ferreri","year":"2022","unstructured":"Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Ros\u00e9e P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, G\u00f8rl\u00f8v JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, Illerhaus G, investigators Is (2022) Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia 36(7):1870\u20131878. https:\/\/doi.org\/10.1038\/s41375-022-01582-5","journal-title":"Leukemia"},{"issue":"1","key":"6939_CR7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/annonc\/mdl327","volume":"18","author":"V Boehme","year":"2007","unstructured":"Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma\u2014a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL). Ann Oncol 18(1):149\u2013157. https:\/\/doi.org\/10.1093\/annonc\/mdl327","journal-title":"Ann Oncol"},{"issue":"4","key":"6939_CR8","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, Wang JQ, Schmitz R, Morin RD, Tang J, Jiang A, Bagaev A, Plotnikova O, Kotlov N, Johnson CA, Wilson WH, Scott DW, Staudt LM (2020) A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell 37(4):551\u2013568e514. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.015","journal-title":"Cancer Cell"},{"issue":"7332","key":"6939_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim K-H, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM (2011) Oncogenically active MYD88 mutations in human lymphoma. Nature 470(7332):115\u2013119. https:\/\/doi.org\/10.1038\/nature09671","journal-title":"Nature"},{"issue":"2","key":"6939_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cell.2020.05.049","volume":"182","author":"L Venturutti","year":"2020","unstructured":"Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, B\u00e9guelin W, Lee TC, Kim Y, Chin CR, Yewdell WT, Raught B, Phillip JM, Jiang Y, Staudt LM, Green MR, Chaudhuri J, Elemento O, Farinha P, Weng AP, Nissen MD, Steidl C, Morin RD, Scott DW, Priv\u00e9 GG, Melnick AM (2020) TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell 182(2):297\u2013316e227. https:\/\/doi.org\/10.1016\/j.cell.2020.05.049","journal-title":"Cell"},{"issue":"1","key":"6939_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1158\/2643-3230.Bcd-22-0007","volume":"4","author":"R Fl\u00fcmann","year":"2023","unstructured":"Fl\u00fcmann R, Hansen J, Pelzer BW, Nieper P, Lohmann T, Kisis I, Riet T, Kohlhas V, Nguyen P-H, Peifer M, Abedpour N, Bosco G, Thomas RK, Kochanek M, Kn\u00fcfer J, Jonigkeit L, Beleggia F, Holzem A, B\u00fcttner R, Lohneis P, Meinel J, Ortmann M, Persigehl T, Hallek M, Calado DP, Chmielewski M, Klein S, G\u00f6thert JR, Chapuy B, Zevnik B, Wunderlich FT, von Tresckow B, Jachimowicz RD, Melnick AM, Reinhardt HC, Knittel G (2023) Distinct Genetically Determined Origins of Myd88\/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies. Blood Cancer Discovery 4(1):78\u201397. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-22-0007","journal-title":"Blood Cancer Discovery"},{"issue":"4","key":"6939_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1182\/blood-2017-12-822171","volume":"133","author":"M Mendeville","year":"2019","unstructured":"Mendeville M, Roemer MGM, van den Hout M, Los-de Vries GT, Bladergroen R, Stathi P, Hijmering NJ, Rosenwald A, Ylstra B, de Jong D (2019) Aggressive genomic features in clinically indolent primary HHV8-negative effusion-based lymphoma. Blood 133(4):377\u2013380. https:\/\/doi.org\/10.1182\/blood-2017-12-822171","journal-title":"Blood"},{"issue":"6","key":"6939_CR13","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/s1474-4422(09)70091-2","volume":"8","author":"PG Morris","year":"2009","unstructured":"Morris PG, Abrey LE (2009) Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 8(6):581\u2013592. https:\/\/doi.org\/10.1016\/s1474-4422(09)70091-2","journal-title":"Lancet Neurol"},{"issue":"7","key":"6939_CR14","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41375-023-01908-x","volume":"37","author":"Y Xia","year":"2023","unstructured":"Xia Y, Sun T, Li G, Li M, Wang D, Su X, Ye J, Ji C (2023) Spatial single cell analysis of tumor microenvironment remodeling pattern in primary central nervous system lymphoma. Leukemia 37(7):1499\u20131510. https:\/\/doi.org\/10.1038\/s41375-023-01908-x","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06939-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06939-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06939-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:58:23Z","timestamp":1776405503000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06939-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6939"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06939-9","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and was approved by the National Cancer Center Institutional Review Board. We obtained written informed consent for publication in print and electronically from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Y.K. has received honorarium from Kyowa Kirin, Nippon Shinyaku, Daiichi Sankyo, and Takeda Pharmaceutical. S.F. has received honorarium from Janssen Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceutical, Amgen, Chugai, AbbVie, AstraZeneca, and Otsuka Pharmaceutical; has received research funding from Chugai Pharmaceutical, Loxo Oncology (Eli Lilly and Company), and Mitsubishi Tanabe Pharma. K.I. has received honorarium from Eli Lilly and Company, Merck Sharp & Dohme, Eisai, Chugai, Novartis, AbbVie, Ono Pharmaceutical, AstraZeneca, Kyowa Kirin, Bristol Myers Squibb, Takeda Pharmaceutical, Pfizer, Janssen Pharmaceutical, Daiichi Sankyo, and Symbio Pharmaceuticals; has received research funding from Merck Sharp & Dohme, Incyte, Eisai, AbbVie, Ono Pharmaceutical, AstraZeneca, Yakult, Kyowa Kirin, Loxo Oncology (Eli Lilly and Company), Bristol Myers Squibb, Daiichi Sankyo, Pfizer, Janssen Pharmaceutical, and Novartis; has received consultancy fee from AbbVie, Ono Pharmaceutical, AstraZeneca, Zenyaku, Kyowa Kirin, Merck Sharp & Dohme, Nippon Shinyaku, Genmab, Mitsubishi Tanabe Pharma, Nippon Kayaku, and Bristol Myers Squibb. K.K. has received honorarium from Ono Pharmaceutical, Eisai, Astellas Pharma, Novartis, Chugai Pharmaceutical, AstraZeneca, Sumitomo Pharma, Kyowa Kirin, Janssen Pharmaceutical, Takeda Pharmaceutical, Otsuka Pharmaceutical, SymBio Pharmaceuticals, Bristol Myers Squibb, Pfizer, Nippon Shinyaku, Daiichi Sankyo, Alexion Pharmaceuticals, AbbVie, Meiji Seika Pharma, Sanofi, Sysmex, Mundipharma, Incyte Corporation, and Kyorin Pharmaceutical; has received research funding from Asahi Kasei Pharma, Eisai, Otsuka Pharmaceutical, Ono Pharmaceutical, Kyowa Kirin, Shionogi, Takeda Pharmaceutical, Sumitomo Dainippon Pharma, Chugai Pharmaceutical, Teijin Pharma, Japan Blood Products Organization, Mochida Pharmaceutical, JCR Pharmaceuticals, Nippon Shinyaku, Chordia Therapeutics, and Meiji Seika Pharma; holds individual stocks in Asahi Genomics; has a patent for Genetic alterations as a biomarker in T-cell lymphomas licensed to Kyoto University and PD-L1 abnormalities as a predictive biomarker for immune checkpoint blockade therapy licensed to Kyoto University; is an Associate Editor of Cancer Science. The other authors declare no potential conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}